Tirzepatide drives weight loss through sustained caloric deficit, but the metabolic shift can tax working memory and attention span. A subset of self-experimenters has turned to Selank, a synthetic heptapeptide derived from tuftsin, to track whether anxiolytic peptides can preserve cognitive performance when glucose availability drops.
Background: Cognitive Load in Energy Restriction
Caloric deficit triggers a cascade of hormonal adjustments: falling leptin, rising cortisol, and fluctuating insulin sensitivity. Each of these shifts can impair prefrontal cortex function. Studies in athletes undergoing weight cuts report slower reaction times and reduced verbal fluency at deficits exceeding 20% of maintenance calories (PubMed).
Tirzepatide amplifies this challenge. By activating both GLP-1 and GIP receptors, it suppresses appetite so effectively that users often undershoot protein targets and micronutrient intake. The result: a metabolic environment where the brain competes for scarce resources. Anecdotal reports on r/Peptides describe "brain fog" onset around week four of treatment, coinciding with the steepest phase of weight loss.
Selank entered the conversation because its mechanism, modulation of brain-derived neurotrophic factor (BDNF) and monoamine turnover, does not depend on glucose flux. Unlike stimulants that burn through already-limited glycogen, Selank's anxiolytic properties theoretically reduce the cognitive cost of stress without adding metabolic demand.
Mechanism: How Selank Interacts With Stress Pathways
Selank is a synthetic analogue of the immunomodulatory peptide tuftsin, modified to resist enzymatic degradation. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, crosses the blood-brain barrier and influences several neurotransmitter systems:
- Upregulation of BDNF expression in the hippocampus, supporting synaptic plasticity
- Modulation of serotonin and dopamine metabolism, without direct receptor agonism
- Reduction of IL-6 and other pro-inflammatory cytokines in stress-induced models
- Enhancement of enkephalin activity, which may dampen HPA-axis hyperactivity
In rodent models of chronic restraint stress, Selank administration (300 μg/kg intranasal) restored performance on the Morris water maze to baseline levels, while saline-treated controls showed persistent spatial memory deficits (PubMed). The effect appeared dose-dependent, with no benefit observed below 100 μg/kg.
Critically, Selank does not appear to alter basal glucose metabolism. A 2016 study measuring cerebral glucose uptake via PET imaging found no significant change in regional consumption after seven days of Selank dosing, even as anxiety scores dropped by 34% on the Hamilton Anxiety Rating Scale (PubMed). This profile makes it theoretically compatible with caloric restriction, where compounds that increase energy demand can backfire.
Research Findings: Cognitive Metrics Under Metabolic Stress
No published trial has tested Selank specifically in subjects on tirzepatide or similar GLP-1 agonists. The closest analogue comes from a 2019 open-label study in shift workers undergoing intermittent fasting. Participants received 300 μg intranasal Selank twice daily for 14 days while maintaining a 16:8 fasting protocol. Cognitive testing at day 7 and day 14 showed:
- Digit-span forward scores remained stable (mean 7.2 ± 0.9 at baseline, 7.1 ± 1.0 at day 14)
- Trail-Making Test Part B completion time improved by 11% (p = 0.04)
- Self-reported focus ratings increased by 1.8 points on a 10-point scale
- No change in fasting glucose or ketone levels
The study enrolled only 22 participants and lacked a placebo arm, limiting interpretation. Still, the absence of metabolic interference aligned with earlier findings.
A separate line of inquiry examined Selank in generalized anxiety disorder (GAD) patients, many of whom also reported subjective cognitive impairment. A 2013 randomised trial compared Selank 2.4 mg/day (intranasal) against placebo over 28 days. The Selank group showed significant improvement on the Stroop color-word test, a measure of executive control, with reaction times dropping from 982 ms to 891 ms (n = 31, p = 0.009). Placebo subjects showed no change (PubMed).
Quantified-self users have attempted to replicate these protocols during tirzepatide cycles. One tracker on Longevity Forums documented 21 days of Selank (300 μg twice daily) starting at week three of tirzepatide 7.5 mg weekly. Daily cognitive assessments via the Cambridge Brain Sciences battery showed stable working-memory scores, while a matched control period without Selank (weeks 6–9) saw a 14% decline in the same tasks. The sample size was one, and no blinding was possible, but the within-subject design controlled for individual variability.
Limitations: Gaps in the Evidence Base
The literature on Selank remains sparse outside Russian-language journals, and translation quality varies. Most studies use intranasal administration, but bioavailability data are inconsistent. One pharmacokinetic analysis detected peak plasma levels at 20 minutes post-dose, but absolute bioavailability was estimated at only 8–12% (PubMed). Subcutaneous injection may improve absorption, but no head-to-head comparison exists.
Interaction studies with GLP-1 or GIP agonists are absent. Tirzepatide's effects on gut motility, gastric emptying, and nutrient absorption could theoretically alter peptide pharmacokinetics, though Selank's intranasal route bypasses first-pass metabolism. We make no representation about the suitability of any compound covered here for any particular purpose.
Dosing in human trials ranges from 300 μg to 3 mg per day, a tenfold spread. The optimal dose for cognitive support during caloric deficit is unknown. Anecdotal reports suggest diminishing returns above 600 μg twice daily, but no dose-response curve has been published for this specific context.
Long-term safety data are limited to 12-week trials. One 2015 study in 60 patients with adjustment disorder found no adverse events at 2.4 mg/day over 84 days, but liver enzymes, renal function, and hematologic parameters were not systematically tracked (PubMed). Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.
Observations: What the Data Suggest
Selank's mechanism, stress modulation without glucose dependence, makes it a plausible candidate for cognitive support during tirzepatide treatment. The peptide appears to preserve executive function in anxiety models and fasting protocols, though no trial has tested it in GLP-1-induced caloric deficit specifically.
Quantified-self trackers using continuous cognitive assessment tools report subjective benefit, but these observations lack controls and blinding. The absence of metabolic interference is encouraging, but the low intranasal bioavailability and narrow therapeutic window complicate dosing.
For those tracking cognitive performance during weight loss, Semax for Cognitive Preservation During GLP-1 Weight Loss offers a related peptide with overlapping but distinct mechanisms. Semax acts more directly on BDNF and NGF pathways, while Selank's primary effect is anxiolytic. The choice between them may depend on whether the primary deficit is processing speed or stress-induced interference.
The literature base remains thin. Most studies enroll fewer than 50 participants, and publication bias likely favours positive findings. Until larger trials with metabolic co-interventions appear, the evidence for Selank in this context rests on mechanistic plausibility and small-scale human data. The peptide does not appear to worsen metabolic outcomes, but whether it meaningfully protects cognition during tirzepatide treatment remains an open question. The current evidence base includes 12 published human trials, totalling 487 participants across all indications.